Trinomab

Zhuhai Trinomab Pharmaceutical Co., Ltd.(referred to as “Trinomab”) is a global, clinical-stage innovative biopharmaceutical company primarily engaged in the development of original, fully human natural monoclonal antibody drugs. The core technology of Trinomab is the next-generation "fully human natural monoclonal antibody integrated technology platform HitmAb®," which is dedicated to developing proprietary, highly differentiated, and efficient fully human natural monoclonal antibody drugs to enhance and improve current medical treatments for infectious diseases, autoimmune diseases, malignant tumors, and other conditions. Using the HitmAb® platform technology, Trinomab has discovered more than 20 different fully human natural monoclonal antibodies, establishing a product pipeline with significant differentiation advantages and global competitiveness. Several key products aim to replace plasma-derived immunoglobulins with recombinant fully human natural monoclonal antibodies, including those targeting tetanus toxin, respiratory syncytial virus, human cytomegalovirus, varicella-zoster virus, and rabies virus. Currently, multiple new products are in rapid industrialization, with some already entering clinical trials. With the mission of "creating clinical value," Trinomab focuses on the research and industrialization of fully human natural monoclonal antibody drugs, striving to develop safer, more effective, accessible, and controllable novel drugs to meet clinical needs and benefit patients worldwide.